Daiichi Sankyo, which bought Ranbaxy in 2008, said it was exploring legal options against the former promoters after the company admitted to selling 30 adulterated drugs in the US. But, the repercussions of this action will impact not only Ranbaxy, but is likely to tarnish the reputation of the Indian generics market and exposes the desperate need for regulatory reform.
